Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
The European Medicines Agency (EMA) said on Monday they continued to support the use of AstraZeneca “in all populations” and warns that their position “concerning this vaccine is clear”, stressing that the balance between the inoculant and the secondary risks remains “positive”.
In a statement, the EMA noted a “bad quote“by Marco Cavaleri, head of vaccines at EMA, and denied that its experts changed their position on AstraZeneca. In addition, he regretted that the text of the interview “contains false information on the scientific considerations” of the regulator on the need to continue to vaccinate European citizens with this vaccine.
In an interview with The imprint, chivalry stated that “it would be better to stop using the AstraZeneca for all age groups when other alternatives are available “, but the EMA insists that the position on the inoculant “has not changed”.
Additionally, he said the benefits, which prevent more deaths and hospitalizations, continue to outweigh the risks of side effects such as the development of thrombosis or the possibility of a bleeding disorder. .
All vaccines approved by the EMA, including that of AstraZeneca, maintain a positive benefit-risk ratio, especially in the elderly and vulnerable, so they should continue to be used, he stressed. chivalry, after the controversy in which it appeared he was urging to avoid the use of AstraZeneca in the EU.
At the beginning of April, the same person in charge of EMA sparked another controversy, when he said that there was a “clear” link between inoculation with AstraZeneca and cases of thromboembolism in vaccinated persons.
After an analysis of the cases, the EMA concluded that there is a “possible link” between thrombi and the vaccine, but clarified that the benefits outweigh the risks.
Many European countries have decided to limit its use to people over 60, and today Chile has suspended the second dose of the vaccine in people under 45.
Regarding the second dose, the European body has recommended to vaccinate those who received the first dose and will not have serious side effects, since the second injection does not have more side effects than the first.
.
[ad_2]
Source link
